A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function
Status:
Completed
Trial end date:
2016-05-19
Target enrollment:
Participant gender:
Summary
To assess the pharmacokinetics of a single oral dose of osilodrostat (LCI699) 30 mg in
subjects with mild, moderate and severe hepatic impairment compared with subjects with normal
hepatic function.